Browsing Tag
Vyepti
3 posts
Lundbeck’s Vyepti shows real-world migraine relief in patients failed by prior CGRP treatments
New INFUSE study data shows Vyepti may improve outcomes in migraine patients unresponsive to CGRP therapies. Find out what this means for the market.
January 30, 2026
Vyepti and Rexulti power Lundbeck (CPH: LUN) to raise 2025 guidance after 22% adjusted EBITDA surge
Lundbeck lifts 2025 guidance as Vyepti and Rexulti drive 22% EBITDA growth. Explore the neuroscience-focused strategy powering its latest earnings surge.
November 12, 2025
Vyepti by H. Lundbeck A/S shows robust Phase IV efficacy in chronic migraine with medication-overuse headache patients
H. Lundbeck A/S reports rapid and significant migraine prevention benefits for Vyepti® (eptinezumab) in Phase IV RESOLUTION trial, targeting MOH patients.
June 21, 2025